Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December
Vaccine Abbreviations | CDC
Moderna on X: "5 Phase 1 studies ongoing; 7 add'l dev programs advancing toward clinic, incl novel #mRNA #vaccines & #mRNA #ImmunoOncology therapeutics https://t.co/IECjtS1XzQ" / X
Moderna vaccine for coronavirus: Efficacy, side effects, and more
What does the Moderna vaccine mean for the fight against Covid? | Coronavirus | The Guardian
Pioneering mRNA technology - Moderna
Moderna – Wikipedia
The Moderna Era | 2021: Summer | Amherst College
Moderna on X: "So proud of the progress our team is making on behalf of patients. Filed an IND for our 10th #mRNA medicine in less than two years! https://t.co/7vFgPFP5vq" / X
Spikevax Name Locked by Moderna in Europe | Fierce Pharma
Moderna COVID-19 vaccine - Wikipedia
The Moderna Era | 2021: Summer | Amherst College
S-1
Vaccines | Free Full-Text | Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response
Read Moderna's 2017 Investor Pitch Deck: Biotech Created Coronavirus Shot
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 | MMWR
Our Story - Moderna
Moderna Harnesses AI to Transform Medicine
EX-99.1
The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability - ScienceDirect
Pfizer and Moderna Are Pushing the New Covid Booster. Should You Get It? The CDC Is About to Decide. - KFF Health News
Rolando Pajon, PhD on LinkedIn: U.S. FDA Authorizes Two COVID Boosters Targeted at Omicron Subvariants
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 | MMWR
Study finds Moderna vaccine reduces symptomatic COVID-19 in young adults
